Cyber security and life science: How does the new NIS2 directive affect your business?

Submitted by christina on
Hands writing on computer
-

IT attacks are becoming increasingly common and pose a growing threat to public organizations and companies. What requirements are placed on cyber security for life science companies? How does the new EU directive NIS2 affect companies developing products for healthcare? How do you get started mapping security risks and working with measures effectively? 

Leap secured for integrating biologics into topical skin creams

Submitted by christina on

Niclas Roxhed, one of the founders of KTH Innovation's spinoff Morningstar Therapeutics, has just secured a 6.1 million SEK research grant from the LEO Foundation. This funding will advance the development of their groundbreaking spiked microneedle spheres – here used to topically deliver nucleic acids to reprogram skin cells and treating atopic eczema in a model. 

New report on life science trends: Healthy Longevity, Precision Medicine, and Next-Generation Therapeutics

Submitted by christina on

What groundbreaking movements are shaping life sciences today? How do these advancements influence our society, healthcare systems, and lifestyles now and in the future? Stockholm Science City has unveiled a report delving into healthy longevity, precision medicine, and next-generation therapeutics, shedding light on key trends in the fields.

“Why innovation districts matter”

Submitted by christina on

A summit that brings together over 200 brilliant minds to discuss how innovation districts contribute to growth and attraction. It’s the summit “Navigating the Future of Innovation Districts”, where experiences and ideas will be shared to reach a new level for innovation districts.  

Healthy longevity, precision medicine and next-generation therapeutics

This report aims to give an overview of some of the current, important advances within life science that were highlighted during the symposium "The Future of Life Science: Healthy Longevity, Next-generation Therapeutics, and Precision Health". The report focuses on key topics which highlight the status, immediate challenges and possibilities for the future. At the end of the document, there are reflections on the key drivers for investments in research and development within life science.

Healthy longevity, precision medicine & next-generation therapeutics.pdf (5.74 MB)

"We have to choose the right path in Life Science"

Submitted by christina on

JENNI NORDBORG: I am hardly exaggerating when I claim that right now, the future of Stockholm, Sweden, and Europe in Life Science is at stake. We have to get EU governments and Brussels bureaucrats to choose the right path – the one that leads to increased companies' research investments, new medicines being researched and developed within the EU, and Life Science clusters like the one we have in Stockholm continuing to develop.

Subscribe to